F. Mela

发表

Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3‐nitropropionic acid: implications for Huntington's disease

S. Hanau, M. Morari, L. Beani, 2003, The European journal of neuroscience.

Pharmacological Modulation of Glutamate Transmission in a Rat Model of l-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling

W. Danysz, M. Cenci, A. Recchia, 2009, Journal of Pharmacology and Experimental Therapeutics.

Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson’s disease

M. Hofmann, W. Danysz, A. Dekundy, 2015, Journal of Neural Transmission.

GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.

C. Parsons, Y. Auberson, Riccardo Viaro, 2013, ACS chemical neuroscience.

Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5‐hydroxytryptamine and noradrenaline release in the rat neocortex

D. Lambert, M. Morari, G. Calo’, 2003, British journal of pharmacology.

The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect l-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats

M. Millan, M. Morari, M. Brocco, 2010, Neuropharmacology.

Blockade of Nociceptin/orphanin Fq Receptor Signaling in Rat Substantia Nigra Pars Reticulata Stimulates Nigrostriatal Dopaminergic Transmission and Motor Behavior ,lys 15 ]n/ofq(1–13)-nh 2 ) (a Selective Nop Receptor Peptide Antagonist) Stimulated It. N/ofq Microinjected in the Sub- Stantia Nigra P

N. Mercuri, G. Franchi, S. Salvadori, 2022 .

Blockade of Nociceptin/Orphanin FQ Transmission Attenuates Symptoms and Neurodegeneration Associated with Parkinson's Disease

S. Salvadori, M. Morari, R. Reinscheid, 2005, The Journal of Neuroscience.

Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group‐II metabotropic and NMDA receptors

M. Morari, L. Beani, M. Marti, 2003, Journal of neurochemistry.

Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease

W. Danysz, M. Cenci, M. Morari, 2007, Journal of neurochemistry.

[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a Highly Potent and Selective Agonist of the Nociceptin/Orphanin FQ Receptor

S. Salvadori, D. Lambert, M. Morari, 2005, Journal of Pharmacology and Experimental Therapeutics.

RAPID COMMUNICATION: Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol‐induced akinesia and normalizes nigral glutamate release

M. Morari, G. Calo’, R. Guerrini, 2004, Journal of neurochemistry.

Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5‐hydroxytryptamine release in the mouse neocortex

S. Salvadori, M. Morari, L. Beani, 2004, The European journal of neuroscience.

Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK‐21273 in comparison with SB‐612111

M. Morari, G. Calo’, M. Budri, 2013, British journal of pharmacology.

Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on l-DOPA-induced dyskinesia

C. Parsons, W. Danysz, M. Hechenberger, 2011, Journal of Neural Transmission.

Striatal dopamine–NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors

M. Morari, L. Beani, M. Marti, 2002, Journal of neurochemistry.

Changes of Glutamatergic Control of Striatal Acetylcholine Release in Experimental Parkinsonism

M. Morari, M. Marti, C. Bianchi, 2005 .

In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels

M. Cenci, M. Morari, M. Marti, 2012, Neurobiology of Disease.

Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: Role of P/Q-type high voltage activated Ca++ channels and endogenous dopamine

C. Missale, M. Morari, C. Fiorentini, 2006, Molecular and Cellular Neuroscience.